Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Change in Receivables: 2018-2024

Historic Change in Receivables for Cidara Therapeutics (CDTX) over the last 7 years, with Dec 2024 value amounting to -$14.3 million.

  • Cidara Therapeutics' Change in Receivables rose 100.31% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$488,000, marking a year-over-year increase of 59.40%. This contributed to the annual value of -$14.3 million for FY2024, which is 237.09% down from last year.
  • As of FY2024, Cidara Therapeutics' Change in Receivables stood at -$14.3 million, which was down 237.09% from $10.4 million recorded in FY2023.
  • Over the past 5 years, Cidara Therapeutics' Change in Receivables peaked at $11.2 million during FY2020, and registered a low of -$14.3 million during FY2024.
  • Its 3-year average for Change in Receivables is -$1.1 million, with a median of $477,000 in 2022.
  • As far as peak fluctuations go, Cidara Therapeutics' Change in Receivables surged by 111,550.00% in 2020, and later plummeted by 237.09% in 2024.
  • Yearly analysis of 5 years shows Cidara Therapeutics' Change in Receivables stood at $11.2 million in 2020, then slumped by 152.12% to -$5.8 million in 2021, then surged by 108.20% to $477,000 in 2022, then surged by 2,083.02% to $10.4 million in 2023, then crashed by 237.09% to -$14.3 million in 2024.